Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 12/2010

01-12-2010 | Original paper

The effect of modifiable potentials on hypermethylation status of retinoic acid receptor-beta2 and estrogen receptor-alpha genes in primary breast cancer

Authors: Saeed Pirouzpanah, Forough A. Taleban, Morteza Atri, Ali-Reza Abadi, Parvin Mehdipour

Published in: Cancer Causes & Control | Issue 12/2010

Login to get access

Abstract

Epigenetic silencing of retinoic acid receptor-beta2 (RARbeta2) and estrogen receptor-alpha (ERalpha) expressions have been revealed to be important in the development of approaches for diagnosis and therapy of breast cancer. We aimed to explore the correlation of some potential factors with the hypermethylation status of RARbeta2 and ERalpha genes among Iranian breast cancer patients. The hypermethylation status was investigated in 137 dissected tissues from primary breast cancer patients through methylation-specific PCR. Overall, the methylation frequencies of RARbeta2 and ERalpha genes were observed in 36.5 and 51.1% of participants, respectively. The hypermethylated RARbeta2 was associated with younger age at diagnosis and negative family history of breast cancer. The hypermethylation of ERalpha was correlated positively with smoking, duration of estradiol exposure, ER-negativity in tumors and body mass index (at 5 years ago). The plasma levels of folate and vitamin B12 were inversely related to the hypermethylation status of ERalpha, after controlling for covariates. The risk of ERalpha hypermethylation was increased with high plasma level of total homocysteine. In conclusion, our data provide new insights into the possible effect of some lifestyle-related factors on the aberrant methylation drift of ERalpha and RARbeta2 genes in breast cancer.
Literature
1.
Widschwendter M, Berger J, Hermann M et al (2000) Methylation and silencing of the retinoic acid receptor-beta2 gene in breast cancer. J Natl Cancer Inst 92:826–832CrossRefPubMed
2.
Atri M, Jafarimojarad E, Javidroozi M, Mehdipour P (2003) Lack of association between early onset of breast cancer and numbers of affected relatives in an Iranian population. Fam Cancer 2:117–118CrossRefPubMed
3.
Fackler MJ, McVeigh M, Evron E et al (2003) DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and twist in in situ and invasive lobular breast carcinoma. Int J Cancer 107:970–975CrossRefPubMed
4.
Rousseaua C, Petterssona F, Couturea MC et al (2003) The N-terminal of the estrogen receptor (ER) mediates transcriptional cross-talk with the retinoic acid receptor in human breast cancer cells. J Steroid Biochem Mol Biol 86:1–14CrossRef
5.
Nass SJ, Herman JG, Gabrielson E et al (2000) Aberrant methylation of the estrogen receptor and E-cadherin 5′ CpG islands increases with malignant progression in human breast cancer. Cancer Res 60:4346–4348PubMed
6.
Lapidus RG, Nass SJ, Butash KA et al (1998) Mapping of ER gene CpG island methylation by methylation-specific polymerase chain reaction. Cancer Res 58:2515–2519PubMed
7.
Herman JG, Graff JR, Myhanen S, Nelkin BD, Baylin SB (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93:9821–9826CrossRefPubMed
8.
Youssef EM, Lotan D, Isaa JP et al (2004) Hypermethylation of the retinoic acid receptor β2 gene in head and neck carcinogenesis. Clin Cancer Res 10:1733–1742CrossRefPubMed
9.
Shukla S, Mirza S, Sharma G et al (2006) Detection of RASSFIA and RARb hypermethylation in serum DNA from breast cancer patients. Epigenetics 1:88–93CrossRefPubMed
10.
Johnson IT, Belshaw NJ (2008) Environment, diet and CpG island methylation: epigenetic signals in gastrointestinal neoplasia. Food Chem Toxicol 46:1346–1359CrossRefPubMed
11.
Bean GR, Ibarra C, Drendall C et al (2007) Hypermethylation of the breast cancer-associated gene 1 promoter does not predict cytologic atypia or correlate with surrogate end points of breast cancer risk. Cancer Epidemiol Biomarkers Prev 16:50–56CrossRefPubMed
12.
Chen Y, Toland AE, McLennan J et al (2006) Lack of germ-line promoter methylation in BRCA1-negative families with familial breast cancer. Genet Test 10:281–284CrossRefPubMed
13.
Baldwin RL, Nemeth E, Tran H et al (2000) BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res 60:5329–5333PubMed
14.
Chan AO, Issa JP, Morris JS, Hamilton SR, Rashid A (2002) Concordant CpG islands methylation in hyperplastic polyposis. Am J Pathol 160:529–536PubMed
15.
Euhus DM, Bu D, Milchgrub S et al (2008) DNA methylation in benign breast epithelium in relation to age and breast cancer risk. Cancer Epidemiol Biomarkers Prev 17:1051–1059CrossRefPubMed
16.
Issa JP (2000) CpG-island methylation in aging and cancer. Curr Top Microbiol Immunol 249:101–118PubMed
17.
Li S, Rong M, Iacopetta B (2006) DNA hypermethylation in breast cancer and its association with clinicopathological features. Cancer Lett 237:272–280CrossRefPubMed
18.
Herceg Z (2007) Epigenetics and cancer: towards an evaluation of the impact of environmental and dietary factors. Mutagenesis 22:91–103CrossRefPubMed
19.
Gunter MJ, Leitzmann MF (2006) Obesity and colorectal cancer: epidemiology, mechanisms and candidate genes. J Nutr Biochem 17:145–156CrossRefPubMed
20.
Nkhata KJ, Ray A, Dogan S, Grande JP, Cleary MP (2009) Mammary tumor development from T47-D human breast cancer cells in obese ovariectomized mice with and without estradiol supplements. Breast Cancer Res Treat 114:71–83CrossRefPubMed
21.
Brait M, Ford JG, Papaiahgari S et al (2009) Association between lifestyle factors and CpG island methylation in a cancer-free population. Cancer Epidemiol Biomarkers Prev 18:2984–2991CrossRefPubMed
22.
Lin RK, Hsieh YS, Lin P et al (2010) The tobacco-specific carcinogen NNK induces DNA methyltransferase 1 accumulation and tumor suppressor gene hypermethylation in mice and lung cancer patients. J Clin Invest 120:521–532CrossRefPubMed
23.
Swafford DS, Middleton SK, Palmisano WA et al (1997) Frequent aberrant methylation of p16INK4A in primary rat lung tumors. Mol Cell Biol 17:1366–1374PubMed
24.
Davis C, Uthus EU (2004) DNA methylation, cancer susceptibility, and nutrient interaction. Exp Biol Med (Maywood) 229:988–995
25.
Kim YI (2004) Folate and DNA methylation: a mechanistic link between folate deficiency and colorectal cancer? Cancer Epidemiol Biomarkers Prev 13:511–519PubMed
26.
Friso S, Choi W, Girelli D et al (2002) A common mutation in the 5, 10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation thorough an interaction with folate status. Proc Natl Acad Sci U S A 99:5606–5611CrossRefPubMed
27.
Eckel RH, Krauss RM (1998) American Heart Association call to action: obesity as a major risk factor for coronary heart disease. Circulation 97:2099–2100PubMed
28.
Cote S, Sinnett D, Momparler RL (1998) Demethylation by 5-aza-2′-deoxycitidine of specific 5-methylcytosine sites in the promoter region of retinoic acid receptor beta gene in human colon carcinoma cells. Anticancer Drugs 9:743–750CrossRefPubMed
29.
Pappas J, Toulouse A, He′bertx J, Fetni R, Bradle WEC (2008) Allelic methylation bias of the RARB2 tumor suppressor gene promoter in cancer. Gene Chromosom Cancer 47:978–993CrossRef
30.
Giacinti L, Claudio PP, Lopez M, Giordano A (2006) Epigenetic information and estrogen receptor alpha expression in breast cancer. Oncologist 11:1–8CrossRefPubMed
31.
Lapidus RG, Ferguson AT, Ottaviano YL et al (1996) Methylation of estrogen and progesterone receptor gene 5′ CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clin Cancer Res 2:805–810PubMed
32.
Wei M, Xu EJ, Dignam J et al (2008) Estrogen receptor a, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers. Breast Cancer Res Treat 111:113–120CrossRefPubMed
33.
McCourt CK, Mutch DG, Gibb RK et al (2007) Body mass index: relationship to clinical, pathologic and features of microsatellite instability in endometrial cancer. Gynecol Oncol 104:535–539CrossRefPubMed
34.
Lai JC, Chen YW, Chio HL et al (2005) Gender difference in estrogen receptor alpha promoter hypermethylation and its prognostic value in non-small cell lung cancer. Int J Cancer 117:974–980CrossRefPubMed
35.
Kim DH, Kim JS, Ji YI et al (2003) Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer. Cancer Res 63:3743–3746PubMed
36.
Gabriel HE, Crott JW, Ghandour H et al (2006) Chronic cigarette smoking is associated with diminished folate status, altered folate form distribution, and increased genetic damage in the buccal mucosa of healthy adults. Am J Clin Nutr 83:835–841PubMed
37.
Zhang S, Hankinson SE, Hunter DJ et al (2005) Folate intake and risk of breast cancer characterized by hormone receptor status. Cancer Epidemiol Biomarkers Prev 14:2004–2008CrossRefPubMed
38.
van Engeland M, Weijenberg MP, Roemen GM et al (2003) Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands cohort study on diet and cancer. Cancer Res 63:3133–3137PubMed
39.
Friso S, Lamon-Fava S, Jang H et al (2007) Oestrogen replacement therapy reduces total plasma homocysteine and enhances genomic DNA methylation in postmenopausal women. Br J Nutr 97:617–621CrossRefPubMed
Metadata
Title
The effect of modifiable potentials on hypermethylation status of retinoic acid receptor-beta2 and estrogen receptor-alpha genes in primary breast cancer
Authors
Saeed Pirouzpanah
Forough A. Taleban
Morteza Atri
Ali-Reza Abadi
Parvin Mehdipour
Publication date
01-12-2010
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 12/2010
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-010-9629-z

Other articles of this Issue 12/2010

Cancer Causes & Control 12/2010 Go to the issue

Original paper

Alcohol consumption and mortality from all-cause and cancers among 1.34 million Koreans: the results from the Korea national health insurance corporation’s health examinee cohort in 2000

Original paper

Progress in addressing disparities through comprehensive cancer control

Original paper

Statins and pancreatic cancer risk: a nested case–control study

Original paper

Increased risk of adenomas in individuals with a family history of colorectal cancer: results of a meta-analysis

Original paper

Public policy action and CCC implementation: benefits and hurdles

Original paper

Light at night and breast cancer risk: results from a population-based case–control study in Connecticut, USA
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits